Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Light Horse Therapeutics is a small molecule drug discovery, pioneering to target that causes disabling and life-threatening diseases.
Borealis Biosciences is a company in the field of next-generation RNA medicines.
Antag Therapeutics provides therapeutic peptides for the treatment of dietary-related metabolic diseases.
858 Therapeutics develops small molecule drugs targeting oncology and immunology.
Kate Therapeutics is a biotechnology company focused on developing next-generation gene therapies for muscle and heart diseases.
LENZ Therapeutics operates as an organization engaged in the late-stage clinical development of pharmaceuticals for the eyes.
Santa Ana Bio is a biotechnology company focusing on precision immunology for autoimmune and inflammatory diseases.
SixPeaks Bio is developing a pipeline of medicines for healthy weight loss.
Firefly Bio specializes in Degrader Antibody Conjugates (DACs) which combine the unique strengths of ADCs with selective protein degraders.
Tentarix creates innovative protein therapeutics with uniquely combined bioactivities that leverage synthetic biology.
Nexo Therapeutics offers treatments for some of cancer's most intractable targets.
Abdera is an oncology company developing targeted alpha therapies (TATs) for patients with relapsed, refractory, and metastatic cancers.
Capsida Biotherapeutics is a biotechnology company that specializes in tackling monogenetic and sporadic CNS and non-CNS disorders.
Launchpad Therapeutics operates as an antibody-focused precision oncology company.
iECURE is a mutation-agnostic in vivo gene editing company striving to cure devastating diseases with high unmet needs.
Jnana Therapeutics develops innovative therapies using a chemoproteomics drug discovery platform.
Anokion is harnessing the power of natural immune equilibrium to develop solutions for antigen-specific immune tolerance.
Vector BioPharma's cutting-edge gene precision delivery technology will transform the safety, efficacy, and specificity of biologics.
Cimeio Therapeutics develops curative treatments for genetic diseases, hematologic malignancies, and severe autoimmune disorders.
CODA Biotherapeutics develops a chemogenetic platform designed to modulate neuronal activity.
SanReno Therapeutics develop, manufacture and commercialize kidney disease therapies.
Repare Therapeutics is a developer of oncology drugs designed to target specific vulnerabilities of tumor cells.
Tarveda Therapeutics is a developer of miniature drug conjugates designed for the treatment of patients with a wide range of solid tumors.
Stablix Therapeutics is a biotechnology company pioneering the field of Targeted Protein Stabilization (TPS).
Versant Ventures has invested in 89 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Versant Ventures's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Life Science. The firm invests across 12 different industry categories.
Among tracked funding rounds, Abdera Therapeutics received $142.0M in a Series B round. Versant Ventures's total known invested capital is $4.4B.
Versant Ventures's average investment size is $68.2M across its portfolio of 89 companies.
Recent Versant Ventures portfolio additions include Light Horse Therapeutics, Borealis Biosciences, Antag Therapeutics, 858 Therapeutics, Kate Therapeutics. These companies were founded in 2020 or later.